Global Drug Repositioning Service 麻豆原创 Research Report 2023

Publication ID:

PB504233345

Publication Date:

April 13, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.
The global Drug Repositioning Service market was valued at US$ 27690 million in 2022 and is anticipated to reach US$ 36480 million by 2029, witnessing a CAGR of 4.7% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Drug Repositioning key players include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, etc. Global top five manufacturers hold a share about 15%.
North America is the largest market, with a share about 40%, followed by Europe and China, both have a share over 30 percent.
In terms of product, Generic Drugs is the largest segment, with a share about 65%. And in terms of application, the largest application is Cancer, followed by Cardiovascular Diseases.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Drug Repositioning Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Repositioning Service.
The Drug Repositioning Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Drug Repositioning Service market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drug Repositioning Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Biovista
Anaxomics Biotech
Segue Therapeutics
GVK Biosciences
LTT Bio-Pharma
Segment by Type
Generic Drugs
Clinical Trial Failed Drugs
Segment by Application
Cardiovascular Diseases
Mental Illness
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Repositioning Service companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Drug Repositioning Service 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Generic Drugs
1.2.3 Clinical Trial Failed Drugs
1.3 麻豆原创 by Application
1.3.1 Global Drug Repositioning Service 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cardiovascular Diseases
1.3.3 Mental Illness
1.3.4 Cancer
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug Repositioning Service 麻豆原创 Perspective (2018-2029)
2.2 Drug Repositioning Service Growth Trends by Region
2.2.1 Global Drug Repositioning Service 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Drug Repositioning Service Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Drug Repositioning Service Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Drug Repositioning Service 麻豆原创 Dynamics
2.3.1 Drug Repositioning Service Industry Trends
2.3.2 Drug Repositioning Service 麻豆原创 Drivers
2.3.3 Drug Repositioning Service 麻豆原创 Challenges
2.3.4 Drug Repositioning Service 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug Repositioning Service Players by Revenue
3.1.1 Global Top Drug Repositioning Service Players by Revenue (2018-2023)
3.1.2 Global Drug Repositioning Service Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Drug Repositioning Service 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drug Repositioning Service Revenue
3.4 Global Drug Repositioning Service 麻豆原创 Concentration Ratio
3.4.1 Global Drug Repositioning Service 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug Repositioning Service Revenue in 2022
3.5 Drug Repositioning Service Key Players Head office and Area Served
3.6 Key Players Drug Repositioning Service Product Solution and Service
3.7 Date of Enter into Drug Repositioning Service 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug Repositioning Service Breakdown Data by Type
4.1 Global Drug Repositioning Service Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Drug Repositioning Service Forecasted 麻豆原创 Size by Type (2024-2029)
5 Drug Repositioning Service Breakdown Data by Application
5.1 Global Drug Repositioning Service Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Drug Repositioning Service Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Drug Repositioning Service 麻豆原创 Size (2018-2029)
6.2 North America Drug Repositioning Service 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Drug Repositioning Service 麻豆原创 Size by Country (2018-2023)
6.4 North America Drug Repositioning Service 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drug Repositioning Service 麻豆原创 Size (2018-2029)
7.2 Europe Drug Repositioning Service 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Drug Repositioning Service 麻豆原创 Size by Country (2018-2023)
7.4 Europe Drug Repositioning Service 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug Repositioning Service 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Drug Repositioning Service 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Drug Repositioning Service 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Drug Repositioning Service 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drug Repositioning Service 麻豆原创 Size (2018-2029)
9.2 Latin America Drug Repositioning Service 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Drug Repositioning Service 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Drug Repositioning Service 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug Repositioning Service 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Drug Repositioning Service 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Drug Repositioning Service 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Drug Repositioning Service 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biovista
11.1.1 Biovista Company Detail
11.1.2 Biovista Business Overview
11.1.3 Biovista Drug Repositioning Service Introduction
11.1.4 Biovista Revenue in Drug Repositioning Service Business (2018-2023)
11.1.5 Biovista Recent Development
11.2 Anaxomics Biotech
11.2.1 Anaxomics Biotech Company Detail
11.2.2 Anaxomics Biotech Business Overview
11.2.3 Anaxomics Biotech Drug Repositioning Service Introduction
11.2.4 Anaxomics Biotech Revenue in Drug Repositioning Service Business (2018-2023)
11.2.5 Anaxomics Biotech Recent Development
11.3 Segue Therapeutics
11.3.1 Segue Therapeutics Company Detail
11.3.2 Segue Therapeutics Business Overview
11.3.3 Segue Therapeutics Drug Repositioning Service Introduction
11.3.4 Segue Therapeutics Revenue in Drug Repositioning Service Business (2018-2023)
11.3.5 Segue Therapeutics Recent Development
11.4 GVK Biosciences
11.4.1 GVK Biosciences Company Detail
11.4.2 GVK Biosciences Business Overview
11.4.3 GVK Biosciences Drug Repositioning Service Introduction
11.4.4 GVK Biosciences Revenue in Drug Repositioning Service Business (2018-2023)
11.4.5 GVK Biosciences Recent Development
11.5 LTT Bio-Pharma
11.5.1 LTT Bio-Pharma Company Detail
11.5.2 LTT Bio-Pharma Business Overview
11.5.3 LTT Bio-Pharma Drug Repositioning Service Introduction
11.5.4 LTT Bio-Pharma Revenue in Drug Repositioning Service Business (2018-2023)
11.5.5 LTT Bio-Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Biovista
Anaxomics Biotech
Segue Therapeutics
GVK Biosciences
LTT Bio-Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.